Igc pharma to present advanced ai platforms for alzheimer's disease at the aaic 2025

- company to showcase innovations in ai-driven drug discovery and early disease detection, including solutions for low resource settings - potomac, maryland / access newswire / july 23, 2025 / igc pharma, inc. (nyse american:igc), a clinical-stage biopharmaceutical company focused on alzheimer's disease, today announced the presentation of three scientific posters at the 2025 alzheimer's association international conference ("aaic"), taking place july 27-31 in toronto, canada. the poster presentations highlight advancements in the company's proprietary artificial intelligence ("ai") platforms designed to accelerate drug discovery and improve early detection of alzheimer's disease, particularly in low-resource settings.
IGC Ratings Summary
IGC Quant Ranking